Results 171 to 180 of about 36,401 (263)

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 11, Page 1819-1830, November 2026.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern   +14 more
wiley   +1 more source

Type 2-low Asthma: Epidemiology, Multiomics, and Emerging Therapies. [PDF]

open access: yesCurr Allergy Asthma Rep
Mendez P, Rosado A, Cardet JC.
europepmc   +1 more source

Mycoplasma pneumoniae Infection in Children: Clinical Features and Outcomes. [PDF]

open access: yesMaedica (Bucur)
Taras R   +3 more
europepmc   +1 more source

Comparative study of preoperative with postoperative diagnosis in acute abdomen. [PDF]

open access: yesAnn Med Surg (Lond)
Bhatta BR   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy